Ventas, Inc.

VTR

US92276F1003

Ventas, Inc. specializes in owning and managing healthcare and medical-residential facilities. At the end of 2022, the group's portfolio included 1,237 assets consisting primarily of senior housing (802), medical office buildings (313), rehabilitation and long-term acute care facilities (36), laboratories and research facilities (32), skilled nursing facilities (16), medical and surgical facilities (13). Net sales are distributed geographically as follows: the United States (88.5%), Canada (10.9%) and the United Kingdom (0.6%).

Sector

Specialized REITs

Calendar

01/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Ventas ramps up acquisitions in property for senior citizens : Ventas CEO

March 09, 2024 at 02:02 am IST

More Strategies

Ratings for Ventas, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

48.91 USD

Average target price

53.26 USD

Spread / Average Target

+8.90%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Healthcare REITs

	1st Jan change	Capi.
VENTAS, INC.	-1.87%	19.72B
WELLTOWER INC.	+12.32%	60.36B
HEALTHPEAK PROPERTIES, INC.	+0.45%	14.05B
OMEGA HEALTHCARE INVESTORS, INC.	-0.10%	7.58B
HEALTHCARE REALTY TRUST INCORPORATED	-6.79%	6.08B
CARETRUST REIT, INC.	+12.06%	3.53B
SABRA HEALTH CARE REIT, INC.	+0.46%	3.35B
AEDIFICA SA	-4.32%	3.2B
MEDICAL PROPERTIES TRUST, INC.	+2.04%	3.07B
NATIONAL HEALTH INVESTORS, INC.	+19.09%	2.89B

Healthcare REITs

Market Closed - Nyse Other stock markets 01:30:01 18/05/2024 am IST			5-day change	1st Jan Change
48.91 ^USD	+0.41%		+2.84%	-1.87%

16/05	Scotiabank Adjusts Price Target on Ventas to $51 From $47	MT
16/05	Morgan Stanley Adjusts Price Target on Ventas to $49 From $47, Keeps Equalweight Rating	MT

Scotiabank Adjusts Price Target on Ventas to $51 From $47	16/05	MT
Morgan Stanley Adjusts Price Target on Ventas to $49 From $47, Keeps Equalweight Rating	16/05	MT
Ventas Maintains Quarterly Dividend at $0.45 per Share; Payable July 18 to Shareholders of Record on July 1	15/05	MT
Ventas, Inc. Declares Second Quarter 2024 Dividend, Payable on July 18, 2024	15/05	CI
Ventas Insider Sold Shares Worth $697,653, According to a Recent SEC Filing	14/05	MT
Jefferies Adjusts Price Target on Ventas to $56 From $52	10/05	MT
Ventas Unit Prices $500 Million Debt Offering	09/05	MT
RBC Capital Adjusts Price Target on Ventas to $52 From $50	07/05	MT
ANALYST RECOMMENDATIONS : Nvidia, The Home Depot, Lowe's, Rollins...	07/05
Evercore ISI Adjusts Ventas' Price Target to $51 From $50, Keeps Outperform Rating	07/05	MT
Wedbush Raises Price Target on Ventas to $54 Form $52, Keeps Outperform Rating	03/05	MT
Transcript : Ventas, Inc., Q1 2024 Earnings Call, May 02, 2024	02/05
Evercore ISI Adjusts Price Target on Ventas to $50 From $49	02/05	MT
Ventas lifts lower-end of annual FFO forecast on strong quarterly demand	02/05	RE
Ventas Q1 Normalized FFO, Revenue Increase	02/05	MT
Earnings Flash (VTR) VENTAS Reports Q1 Revenue $1.2B	02/05	MT
Ventas, Inc. Updates Earnings Guidance for the Full Year 2024	02/05	CI
Ventas, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05	CI
Morning Bid: Mayday for bonds as 2024 Fed cut hopes dwindle	01/05	RE
Ventas, Inc. acquired Franklin Park TPC Parkway.	01/05	CI
Evercore ISI Adjusts Price Target on Ventas to $49 From $50	29/04	MT
Ventas, Inc. Closes Extended and Improved $2.75 Billion Unsecured Credit Facility	25/04	CI
Evercore ISI Upgrades Ventas to Outperform From In Line, Price Target is $50	18/03	MT
Ventas, Inc. Declares First Quarter 2024 Dividend, Payable on April 18, 2024	13/03	CI
Ventas ramps up acquisitions in property for senior citizens : Ventas CEO	09/03	MT